Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has provided an announcement.
TempraMed has entered a strategic media partnership with Dr. Phil’s Envoy Media that grants it access to an audience of roughly 19 million monthly viewers across U.S. broadcast and digital platforms. As exclusive title sponsor of a 44-minute Dr. Phil television special on prescription medication safety airing in May 2026, TempraMed will be featured as the primary solution for mitigating temperature-related medication risks, with integrated on-air interviews, calls-to-action, and persistent branding. The multi-platform campaign spans TV, podcasts, YouTube, and social media, and includes full content usage rights, enabling TempraMed to repurpose material for digital marketing, enterprise sales, payor engagement, and international expansion. This partnership is intended to shift the company from basic awareness-building to scaled demand generation and enterprise engagement, strengthening its brand authority in the U.S. market for temperature-sensitive medication management.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-technology company specializing in temperature-controlled medication storage solutions. Its patented, FDA-registered devices, such as VIVI Cap and VIVI Epi, use space-grade thermal insulation to protect temperature-sensitive medications 24/7 without batteries or external power. With operations across North America, Europe, and Asia and a smart technology platform in development, the company targets patients, healthcare providers, and enterprises seeking reliable medication protection and adherence tools.
Average Trading Volume: 45,181
Current Market Cap: C$73.44M
For detailed information about VIVI stock, go to TipRanks’ Stock Analysis page.